16 December 2022

JIXING Announces the Appointment of Sandy Mou as Chief Executive Officer

Shanghai, China, December 16th, 2022 – Ji Xing Pharmaceuticals Limited (JIXING), a clinical-stage biopharmaceutical company committed to bringing innovative medicines to underserved Chinese patients with serious and life-threatening diseases, today announces the appointment of Sandy Mou as Chief Executive Officer, effective January 3, 2023. Dr. Peter Fong, the current Chief Executive Officer will continue to serve as Board Executive Director of JIXING.

Sandy Mou has nearly 30 years of experience in the pharmaceutical and medical device industry in China and has held management positions at several multinational pharmaceutical companies including GSK, AstraZeneca, Xi’an Janssen, Johnson & Johnson Medical and MSD. She has led teams to successfully launch several leading brands covering a wide range of therapeutic areas including cardiovascular and metabolic diseases, orthopedics, immunology and oncology. In May 2017, Sandy joined MSD China to establish the oncology business unit and oversaw several product launches including Keytruda. Under her leadership, the MSD China’s oncology business was ranked among the top three oncology businesses of multinational pharmaceutical companies in China after just three years. In March 2020, Sandy joined Shanghai Allist Pharmaceutical Technology Co. (Allist) as the Chief Executive Officer. During her tenure, Allist was successfully listed on the Science and Technology Board of the Shanghai Stock Exchange, achieved the first new drug approval, commercial launch and listing in the National Reimbursement Drug List. Under Sandy’s leadership, Allist has completed the transformation from a biotech company to an innovative biopharmaceutical company with integrated R&D, manufacturing and commercialization capabilities and has achieved profitability.

“We are pleased to welcome Sandy to JIXING. Sandy has been working in the healthcare industry in China for nearly 30 years and has diversified management experience in both multinational companies and Chinese listed companies. In the recent two years, she has successfully led a new product launch, the IPO and the business transformation of a domestic biopharmaceutical company,” said Dr. Peter Fong, Board Executive Director of JIXING. “JIXING has established a strong product pipeline and business foundation. We believe Sandy will bring critical leadership to our further development.”

“I am deeply touched by JIXING’s mission to bridge the innovation gap for patients in China and the world. This is what attracted me most to join JIXING,” said Sandy Mou, incoming Chief Executive Officer of JIXING. “With the focus on cardiovascular and ophthalmic diseases, JIXING has already built an innovative product pipeline and an excellent leadership team. I look forward to working closely with the leadership team to transform JIXING into a biopharmaceutical company with sustainable innovation capabilities based in China and with global reach.”

Additional information

JIXING is a biopharmaceutical company headquartered in Shanghai committed to bringing innovative science and medicines to underserved patients in China with serious and life-threatening diseases. Backed by RTW Investments, LP, JIXING was founded in 2019 and partners with global biotechnology companies to develop and commercialize novel, innovative therapeutics to treat unmet medical needs in cardiovascular and ophthalmic diseases. With a strong and further developing asset pipeline, seasoned management team, and patient-centric focus, JIXING is dedicated to delivering a meaningful and lasting impact on patients in China. For additional information about JIXING, visit www.jixing.com.


Media Contact

Ji Xing Pharmaceuticals